US 11,730,707 B2
Compounds for treating von Hippel-Lindau disease
Luisa María Botella Cubells, Madrid (ES); Virginia Albiñana Díaz, Madrid (ES); and Karina Villar Gomez-De Las Heras, Olías del Rey (ES)
Assigned to ALIANZA ESPAÑOLA DE FAMILIAS DE VON HIPPEL-LINDAU-VHL, Olías del Rey (ES); and CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, Madrid (ES)
Appl. No. 16/636,959
Filed by CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, Madrid (ES); and ALIANZA ESPAÑOLA DE FAMILIAS DE VON HIPPEL-LINDAU-VHL, Olías del Rey (ES)
PCT Filed Aug. 6, 2018, PCT No. PCT/EP2018/071220
§ 371(c)(1), (2) Date Feb. 6, 2020,
PCT Pub. No. WO2019/030151, PCT Pub. Date Feb. 14, 2019.
Claims priority of application No. ESP201731019 (ES), filed on Aug. 7, 2017.
Prior Publication US 2020/0323798 A1, Oct. 15, 2020
Int. Cl. A61K 31/138 (2006.01); A61P 35/04 (2006.01)
CPC A61K 31/138 (2013.01) [A61P 35/04 (2018.01)] 12 Claims
 
1. A method of treatment of von Hippel-Lindau disease in a patient comprising administering to said patient a therapeutically effective amount of a selective antagonist of the B2-adrenergic receptor selected from a compound of formula (II)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable acid-addition salt thereof, and
wherein said patient has a heterozygous germline pathogenic von Hippel-Lindau disease variant.